4-1BB (CD137) Ligand Enhanced Anti-Tumor Immune Response against Mouse Forestomach Carcinoma In Vivo

被引:0
|
作者
Qiaoxia Li1
2The Ninth Hospital of Shijiazhuang
机构
关键词
4-1BBL; CTL; anti-tumor; TIL;
D O I
暂无
中图分类号
R73-36 [治疗实验];
学科分类号
100214 ;
摘要
Cancer occurrence and development has been demonstrated to be associated with escape from immune surveillance, and low costimulatory molecules expression has been considered as one of the important reasons for cancer evading the immune system. 4-1BB (CD137) is a costimulatory molecule expressed on the surface of activated T cells. Interaction of 4-1BB with its natural ligand (4-1BBL) expressed on antigen presenting cells (APCs) has been shown to amplify T-cell mediated immunity. We therefore examined whether murine cancer cells expressing 4-1BBL could produce anti-tumor effects in inoculated mice. Mouse forestomach carcinoma (MFC) cells were transfected with 4-1BBL gene (MFC/4-1BBL). The proliferation of the transduced cells in vitro was not different from that of parental cells. However, MFC/4-1BBL cells developed small tumors and induced higher cytotoxicity of tumor infiltration lymphocyte (TIL). Production of cytokines (IFN-γ, TNF-α and IL-2) in serum and cytotoxic T lymphocyte (CTL) activity of splenocytes from mice immunized with mitomycin C (MMC)-treated MFC/4-1BBL cells were significantly higher than that from mice immunized with MMC-treated parental MFC and MFC/ pMKITneo cells. These results suggest that modification of cancer cells with 4-1BBL gene can produce anti-tumor immune responses.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 50 条
  • [1] 4-1BB (CD137) Ligand Enhanced Anti-Tumor Immune Response against Mouse Forestomach Carcinoma In Vivo
    Qiaoxia Li
    Jun Ai
    Zhenchuan Song
    Jie Liu
    Baoen Shan
    Cellular & Molecular Immunology, 2008, 5 : 379 - 384
  • [2] 4-1BB (CD137) Ligand Enhanced Anti-Tumor Immune Response against Mouse Forestomach Carcinoma In Vivo
    Li, Qiaoxia
    Ai, Jun
    Song, Zhenchuan
    Liu, Jie
    Shan, Baoen
    CELLULAR & MOLECULAR IMMUNOLOGY, 2008, 5 (05) : 379 - 384
  • [3] Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells
    Salih, HR
    Kosowski, SG
    Haluska, VF
    Starling, GC
    Loo, DT
    Lee, F
    Aruffo, AA
    Trail, PA
    Kiener, PA
    JOURNAL OF IMMUNOLOGY, 2000, 165 (05): : 2903 - 2910
  • [4] Immune responses in 4-1BB (CD137)-deficient mice
    Kwon, BS
    Hurtado, JC
    Lee, ZH
    Kwack, KB
    Seo, SK
    Choi, BK
    Koller, BH
    Wolisi, G
    Broxmeyer, HE
    Vinay, DS
    JOURNAL OF IMMUNOLOGY, 2002, 168 (11): : 5483 - 5490
  • [5] Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival
    Cho, HR
    Kwon, B
    Yagita, H
    La, S
    Lee, EA
    Kim, JE
    Akiba, H
    Kim, J
    Suh, JH
    Vinay, DS
    Ju, SA
    Kim, BS
    Mittler, RS
    Okumura, K
    Kwon, BS
    TRANSPLANT INTERNATIONAL, 2004, 17 (07) : 351 - 361
  • [6] 4-1BB (CD137) in anticancer chimeras
    Melero, Ignacio
    Berraondo, Pedro
    JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 217 (12):
  • [7] The therapeutic potential of 4-1BB (CD137) in cancer
    Nam, KO
    Kang, WJ
    Kwon, BS
    Kim, SJ
    Lee, HW
    CURRENT CANCER DRUG TARGETS, 2005, 5 (05) : 357 - 363
  • [8] Tumor cells express the ligand for the tumor necrosis factor receptor family member 4-1BB (CD137/ILA)
    Salih, H
    Loo, D
    Stetsko, D
    Kosowski, S
    Aruffo, A
    Kiener, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S13 - S13
  • [9] Expression of 4-1BB(CD137) and its ligand 4-1BBL in human atherosclerosis
    Ghaderi, M
    Wågsäter, D
    Olofsson, P
    Sheikine, Y
    Sirsjö, A
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 6 - 6
  • [10] CD137 (4-1BB) and T-Lymphocyte Exhaustion
    Molero-Glez, Paula
    Azpilikueta, Arantza
    Mosteo, Laura
    Glez-Vaz, Javier
    Palencia, Belen
    Melero, Ignacio
    CLINICAL CANCER RESEARCH, 2024, 30 (18) : 3971 - 3973